INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation

Authors
Category Primary study
JournalBrain and Spine
Year 2024
This article has no abstract
Epistemonikos ID: 94558092c648e1abb6708f79b0ea72802b40af9a
First added on: Feb 19, 2025